JMP Securities Maintains Market Outperform on Macrogenics, Lowers Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Silvan Tuerkcan has maintained a Market Outperform rating on Macrogenics (NASDAQ:MGNX) but has lowered the price target from $22 to $16.
May 10, 2024 | 4:54 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JMP Securities maintains a Market Outperform rating on Macrogenics but lowers the price target from $22 to $16, indicating a positive outlook but with reduced short-term price expectations.
While the maintenance of a Market Outperform rating suggests continued confidence in Macrogenics' fundamentals and potential for growth, the reduction in the price target may reflect adjustments in market conditions, expected performance, or both. This could lead to mixed reactions in the short term, as investors weigh the positive rating against the lowered price expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100